Is ProMIS Neurosciences Stock a Good Investment?
ProMIS Neurosciences Investment Advice | PMN |
- Examine ProMIS Neurosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ProMIS Neurosciences' leadership team and their track record. Good management can help ProMIS Neurosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ProMIS Neurosciences' business and its evolving consumer preferences.
- Compare ProMIS Neurosciences' performance and market position to its competitors. Analyze how ProMIS Neurosciences is positioned in terms of product offerings, innovation, and market share.
- Check if ProMIS Neurosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ProMIS Neurosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ProMIS Neurosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ProMIS Neurosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ProMIS Neurosciences Stock
Researching ProMIS Neurosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 28.0% of the company outstanding shares are owned by corporate insiders. The book value of ProMIS Neurosciences was at this time reported as 0.22. The company had not issued any dividends in recent years. ProMIS Neurosciences had 1:60 split on the 28th of June 2022.
To determine if ProMIS Neurosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ProMIS Neurosciences' research are outlined below:
| ProMIS Neurosciences generated a negative expected return over the last 90 days | |
| ProMIS Neurosciences has some characteristics of a very speculative penny stock | |
| ProMIS Neurosciences has high historical volatility and very poor performance | |
| ProMIS Neurosciences has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (17.51 M) with loss before taxes, overhead, and interest of (8.54 M). | |
| ProMIS Neurosciences has about 8.95 M in cash with (14.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting |
ProMIS Neurosciences Quarterly Accounts Payable |
|
ProMIS Neurosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ProMIS Neurosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProMIS Neurosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact ProMIS Neurosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ProMIS Neurosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.33 | -0.19 | 0.14 | 42 | ||
2024-11-12 | 2024-09-30 | -0.07 | 0.4344 | 0.5044 | 720 |
Know ProMIS Neurosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProMIS Neurosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProMIS Neurosciences backward and forwards among themselves. ProMIS Neurosciences' institutional investor refers to the entity that pools money to purchase ProMIS Neurosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fiduciary Trust Co | 2024-12-31 | 13.6 K | Scotia Capital Inc | 2024-12-31 | 12.1 K | Claret Asset Management Corporation | 2024-12-31 | 11.3 K | Royal Bank Of Canada | 2024-12-31 | 5.5 K | Sandy Spring Bank | 2024-12-31 | 3.3 K | Bank Of America Corp | 2024-12-31 | 1.7 K | Td Waterhouse Canada Inc | 2024-12-31 | 133 | Affinity Asset Advisors, Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-09-30 | 0.0 | Great Point Partners Llc | 2024-12-31 | 2.6 M | Armistice Capital, Llc | 2024-12-31 | 2.5 M |
ProMIS Neurosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 20.92 M.Market Cap |
|
ProMIS Neurosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.87) | (0.92) | |
| Return On Capital Employed | (3.01) | (3.16) | |
| Return On Assets | (0.87) | (0.92) | |
| Return On Equity | (3.17) | (3.33) |
Determining ProMIS Neurosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if ProMIS Neurosciences is a good buy. For example, gross profit margin measures ProMIS Neurosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ProMIS Neurosciences' profitability and make more informed investment decisions.
Evaluate ProMIS Neurosciences' management efficiency
ProMIS Neurosciences has Return on Asset of (0.4335) % which means that on every $100 spent on assets, it lost $0.4335. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0803) %, meaning that it generated no profit with money invested by stockholders. ProMIS Neurosciences' management efficiency ratios could be used to measure how well ProMIS Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to drop to -0.92. In addition to that, Return On Capital Employed is likely to drop to -3.16. At this time, ProMIS Neurosciences' Total Assets are very stable compared to the past year. As of the 24th of March 2025, Other Assets is likely to grow to 1.21, while Non Current Assets Total are likely to drop about 24.5 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.47 | 0.44 | |
| Net Current Asset Value | 583.44 | 518.62 | |
| Tangible Asset Value | 638.17 | 567.26 | |
| Tangible Book Value Per Share | 0.47 | 0.44 | |
| Enterprise Value Over EBITDA | 0.13 | 0.14 | |
| Price Book Value Ratio | 3.27 | 3.11 | |
| Enterprise Value Multiple | 0.13 | 0.14 | |
| Price Fair Value | 3.27 | 3.11 | |
| Enterprise Value | -2.9 M | -2.8 M |
ProMIS Neurosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.584 |
Basic technical analysis of ProMIS Stock
As of the 24th of March, ProMIS Neurosciences holds the Coefficient Of Variation of (836.13), risk adjusted performance of (0.1), and Variance of 16.43. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProMIS Neurosciences, as well as the relationship between them.ProMIS Neurosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProMIS Neurosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProMIS Neurosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProMIS Neurosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand ProMIS Neurosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ProMIS Neurosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 1.51 | |||
| Mean Deviation | 3.08 | |||
| Coefficient Of Variation | (836.13) | |||
| Standard Deviation | 4.05 | |||
| Variance | 16.43 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.19) | |||
| Treynor Ratio | 1.5 | |||
| Maximum Drawdown | 20.12 | |||
| Value At Risk | (6.06) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.7726 | |||
| Kurtosis | 1.03 |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | 1.51 | |||
| Mean Deviation | 3.08 | |||
| Coefficient Of Variation | (836.13) | |||
| Standard Deviation | 4.05 | |||
| Variance | 16.43 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (0.19) | |||
| Treynor Ratio | 1.5 | |||
| Maximum Drawdown | 20.12 | |||
| Value At Risk | (6.06) | |||
| Potential Upside | 7.69 | |||
| Skewness | 0.7726 | |||
| Kurtosis | 1.03 |
Consider ProMIS Neurosciences' intraday indicators
ProMIS Neurosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProMIS Neurosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ProMIS Neurosciences time-series forecasting models is one of many ProMIS Neurosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProMIS Neurosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ProMIS Stock media impact
Far too much social signal, news, headlines, and media speculation about ProMIS Neurosciences that are available to investors today. That information is available publicly through ProMIS media outlets and privately through word of mouth or via ProMIS internal channels. However, regardless of the origin, that massive amount of ProMIS data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ProMIS Neurosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ProMIS Neurosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ProMIS Neurosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ProMIS Neurosciences alpha.
ProMIS Neurosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ProMIS Neurosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ProMIS Neurosciences Corporate Management
| Gail Farfel | Chief Officer | Profile | |
| Daniel MBA | Chief Officer | Profile | |
| Johanne Kaplan | Chief Officer | Profile | |
| Dennis Chen | Head Consultant | Profile | |
| David Wishart | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between ProMIS Neurosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.